Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

被引:651
作者
Stangier, Joachim [1 ]
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
关键词
D O I
10.2165/00003088-200847050-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The direct thrombin inhibitor dabigatran etexilate is currently in phase III of development for the prophylaxis and treatment of thromboembolic disorders, with three trials completed in primary venous thromboembolism (VTE) prevention. Dabigatran etexilate is an orally administered prodrug, which is rapidly absorbed and converted to the active form, dabigatran. Dabigatran has been shown to specifically and reversibly inhibit thrombin, the key enzyme in the coagulation cascade. Studies in healthy volunteers and in patients undergoing orthopaedic surgery have indicated that dabigatran has a predictable pharmacokinetic/pharmacodynamic profile, allowing for a fixed-dose regimen. Peak plasma concentrations of dabigatran are reached approximately 2 hours after oral administration in healthy volunteers, with no unexpected accumulation of drug concentrations upon multiple dosing. Excretion is predominantly via the renal route as unchanged drug. Dabigatran is not metabolized by cytochrome P450 isoenzymes. The small differences in dabigatran pharmacokinetics associated with age and gender are attributed to variations in renal function. Additional studies have shown that the pharmacokinetic/pharmacodynamic profile of dabigatran is consistent across a range of patient populations, with no effect of moderate hepatic impairment being observed. Drug-drug interactions are not observed with concomitant administration of atorvastatin, diclofenac or digoxin. The pharmacodynamic profile of dabigatran demonstrates effective anticoagulation combined with a low risk of bleeding. Further phase III studies are ongoing, including acute VTE treatment and stroke prevention in atrial fibrillation; the results obtained so far show that dabigatran etexilate is well tolerated and effective in the treatment and prevention of thromboembolic events.
引用
收藏
页码:285 / 295
页数:11
相关论文
共 40 条
[1]   The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].
Blech, Stefan ;
Ebner, Thomas ;
Ludwig-Schwellinger, Eva ;
Stangier, Joachim ;
Roth, Willy .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399
[2]  
CAPRINI JA, 2007, 21 C INT SOC THROMB
[3]   Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis [J].
Cullberg, M ;
Eriksson, UG ;
Wåhlander, K ;
Eriksson, H ;
Schulman, S ;
Karlsson, MO .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (04) :279-290
[4]   Drug therapy -: Direct thrombin inhibitors [J].
Di Nisio, M ;
Middeldorp, S ;
Büller, HR .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (10) :1028-1040
[5]   A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial [J].
Eriksson, BI ;
Dahl, OE ;
Büller, HR ;
Hettiarachchi, R ;
Rosencher, N ;
Bravo, ML ;
Ahnfelt, L ;
Piovella, F ;
Stangier, J ;
Kälebo, P ;
Reilly, P .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :103-111
[6]   Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement:: BISTRO I [J].
Eriksson, BI ;
Dahl, OE ;
Ahnfelt, L ;
Kälebo, P ;
Stangier, J ;
Nehmiz, G ;
Hermansson, K ;
Kohlbrenner, V .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (09) :1573-1580
[7]  
ERIKSSON BI, 2007, 21 C INT SOC THROMB
[8]  
FRIEDMAN RJ, 2007, 21 C INT SOC THROMB
[9]  
GARNETT C, 2003, ANN M AM ASS PHARM S
[10]   The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: A mini-review [J].
Gustafsson, D ;
Elg, M .
THROMBOSIS RESEARCH, 2003, 109 :S9-S15